Omega 3 Vegan Oil of Algae DHA+EPA - 90 Capsules

BACKGROUND Docosahexaenoic acid (DHA) is a critical dietary supplement for vulnerable populations (e.g., infants, pregnant women), but contamination by per- and polyfluoroalkyl substances (PFAS)-persistent "forever chemicals"-poses potential health risks. Currently, no standardized methods exist for PFAS detection in DHA products, hindering quality control and risk assessment. OBJECTIVE To develop and validate a sensitive LC-MS/MS method for simultaneous determination of four PFAS (PFOA, PFODA, PFOS, and PFBS) in DHA matrices (algal oil and fish oil) and support product safety evaluation. METHODS Samples were extracted with 50% methanol/acetonitrile (v/v) via ultrasonication (40 °C, 20 min), followed by centrifugation and filtration. Chromatographic separation was achieved on a Phenomenex Kinetex F5 column (100 × 3.0 mm, 2.6 μm) with gradient elution (mobile phase: 2 mmol/L ammonium formate aqueous solution-methanol) in 12 min. Detection was performed via negative electrospray ionization (ESI-) in multiple reaction monitoring (MRM) mode. Method validation included linearity, limits of detection (LODs)/quantitation (LOQs), accuracy, precision, matrix effects, and stability. Thirteen commercial DHA products (11 algal oil, 2 fish oil) were analyzed. RESULTS Linearity (r ≥ 0.99) were achieved for PFAS; LODs/LOQs: 0.02/0.04 ng/mL. Recoveries at three spiking levels (0.1, 0.5, 1.0, 1.5 ng/mL) were ranged from 92.1%-108.4%, with RSDs of 2.8%-5.6%. Matrix effects were effectively corrected via matrix-matched calibration. Trace PFAS were detected in 3/13 samples, all below regulatory limits. CONCLUSIONS The developed method is reliable for routine PFAS detection in DHA matrixes, providing practical technical support for quality control and risk assessment for DHA supplements for vulnerable populations. HIGHLIGHTS Rapid (12 min), sensitive, and applicable to both algal oil and fish oil matrixes.

ABSTRACT This study investigated the anti‐aging effects of algal Omega3‐DHA in senescence‐accelerated mice (SAM). Male and female SAMP8 mice (3 months old) were divided into a control group and four experimental groups (1× or 2× algal Omega3‐DHA, with/without phospholipids). The mice were orally administered test samples dissolved in corn oil daily for 13 weeks. Aging scores were significantly lower in male mice across all experimental groups and in female mice in the phosphatidylcholine (PC) and phosphatidylserine (PS) (p < 0.05) groups. Learning and memory improved significantly in all the experimental groups (p < 0.05). Brain biomarkers of aging, including 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG), thiobarbituric acid‐reactive substances (TBARS), protein carbonyl content, and β‐amyloid (Aβ) protein, were significantly reduced, while liver antioxidant enzyme activities, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), were increased in the PC and PS groups (p < 0.05). Additionally, survival times were extended in both male and female mice compared to controls. No adverse effects were observed in terms of body weight or activity level. In summary, algal Omega3‐DHA supplementation improved cognitive performance, enhanced antioxidant defenses, reduced aging markers, and delayed aging in SAM mice, highlighting its potential as a promising anti‐aging strategy.

Abstract Behavioral reactivity in horses poses a welfare and safety risk to both the horse and the handler, however, beneficial effects have been observed when dietary fat is increased in replacement of sugar. Supplementation with the fatty acids (FA) eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) appear to improve negative behaviors in rodents and humans, but the effect of α-linolenic acid (ALA), EPA, and DHA, specifically, on reactivity in horses is unknown. The objective of this study was to evaluate the effects of camelina oil (CAM; ALA-enriched) and a mix of camelina and algal oil (ALG; ALA-, EPA-, and DHA-enriched) both fed at a dose of 0.37 g oil/kg body weight on plasma FA, behavior, and heart rate variability (HRV) in young horses compared to a negative control (CON). Thirty-four client-owned horses aged 7 mo to 6 yr were enrolled. Horses were assigned to either CAM, ALG, or CON and underwent a novel object test (NOT) before and after a 6-wk supplementation period. Prior to each NOT, blood was collected for evaluation of plasma FA profile (n = 28). During the NOT, behavior was recorded using a predetermined ethogram and assessed in BORIS software by 2 raters (n = 29). Electrocardiogram (ECG) data was collected at baseline, during the NOT, and after the NOT (recovery). The ECG data was analyzed in Kubios software for determination of heart rate (HR) and several HRV parameters (n = 24). The treatment oils were treated as fixed effects, baseline measurements as covariates, and location as a random effect. Plasma DHA (P < 0.01) was greater and n-6:n-3 ratio (P < 0.01) was reduced in ALG than in CAM and CON, while ALA and EPA were similar among treatments (P > 0.05). When treatments were pooled, the maximum HR (P < 0.01) and the low frequency to high frequency ratio HRV parameter (P < 0.01) were greater during the NOT compared to baseline and recovery. Bucking (P = 0.03) and backing (P = 0.02) behaviors were reduced in the CAM group compared to the CON gr

Background and Objectives: We have previously reported that omega-3 polyunsaturated fatty acids (PUFAs) derived from fish oil (FO) is an effective treatment for type 1 and type 2 diabetes neural and vascular complications. As omega-3 PUFAs become more widely used as a nutritional and disease modifying supplement an important question to be addressed is what is the preferred source of omega-3 PUFAs? Methods: Using a type 2 diabetic rat model and early and late intervention protocols we examined the effect of dietary treatment with omega-3 PUFAs derived from menhaden (fish) oil (MO), krill oil (KO), algal oils consisting primarily of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or combination of EPA + DHA, or pharmaceutical-derived ethyl esters of EPA, DHA or combination of EPA + DHA. Nerve related endpoints included motor and sensory nerve conduction velocity, heat sensitivity of the hind paw, intraepidermal nerve density, cornea nerve fiber length, and cornea sensitivity. Vascular reactivity to acetylcholine and calcitonin gene-related peptide by epineurial arterioles that provide blood to the sciatic nerve was also examined. Results: The dose of each omega-3 PUFA supplement increased the content of EPA, docosapentaenoic acid (DPA), and/or DHA in red blood cell membranes, serum and liver. Diabetes caused a significant decrease of 30–50% of neural function and fiber occupancy of the skin and cornea and vascular reactivity. Treatment with MO, KO or the combination of EPA + DHA provided through algal oil or ethyl esters provided significant improvement of each neural endpoint and vascular function. Algal oil or ethyl ester of EPA alone was the least effective with algal oil or ethyl ester of DHA alone providing benefit that approached combination therapies for some endpoints. Conclusions: We confirm that omega-3 PUFAs are an effective treatment for DPN and sources other than fish oil are similarly effective.